B-Cell Lymphomas Coverage from Every Angle

Recent News

BTK Inhibitor Zanubrutinib Under Study in the Treatment of Resistant DLBCL
Phase II ZUMA-12 Trial Evaluates First-Line Use of Axicabtagene Ciloleucel in High-Risk LBCL
Predicting Remission With CAR T-Cell Therapy in Large B-Cell Lymphoma: Focus on FDG-PET Imaging
CD20-CD3 Bispecific Antibody Under Study in Resistant B-Cell Non-Hodgkin Lymphoma
Can ctDNA Analysis Be Used to Predict Outcomes in High-Risk DLBCL?
AKT Inhibitor Capivasertib Focus of Phase II Trial in B-Cell NHL
AACR 2022: Investigational BCL2 Inhibitors Demonstrate Varying Levels of Antilymphoma Activity
AACR 2022: Pharmacologic Attributes of Axicabtagene Ciloleucel and Therapeutic Index in Lymphoma
AACR 2022: Novel Microtubule-Targeting Agent Demonstrates Antilymphoma Activity
AACR 2022: Can BCL2 Family Protein Dephosphorylation Resensitize Venetoclax-Induced Apoptosis?
AACR 2022: Impact of PRMT5 Inhibition on BH3 Mimetic Sensitivity in Mantle Cell Lymphoma
AACR 2022: Predicting Response/Resistance to Brexucabtagene Autoleucel in Mantle Cell Lymphoma
AACR 2022: Can Decitabine Sensitize DLBCL Cells to Venetoclax?
Adding EP4 Receptor Agonists to CD20 Antigen Therapy in B-Cell Malignancies
Axicabtagene Ciloleucel Receives FDA Approval in Large B-Cell Lymphoma
Predicting Tolerability to Immunochemotherapy in DLBCL: Novel Tool Under Study
Using Targeted Induction Therapy to Minimize Chemotherapy Exposure in Mantle Cell Lymphoma
FDA Brief: Epcoritamab Granted Orphan Drug Designation in Follicular Lymphoma
Phase I Dose-Escalation Study of Mosunetuzumab in B-Cell Lymphomas
New ROR1-Targeting Antibody-Drug Conjugate Under Study in Treatment of Lymphoid Cancers
Aberrations of TP53 and Associated Outcomes With Immunotherapy for LBCL
Could Iron Homeostasis Be a Therapeutic Target in Diffuse Large B-Cell Lymphoma?
Exploring the Combination of PD-1 and CDK9 Inhibitors in Hematologic Cancers
CD20-CD3 Bispecific Antibody Plus Chemotherapy for High-Risk DLBCL
Axicabtagene Ciloleucel in High-Risk Large B-Cell Lymphoma: Primary Analysis of ZUMA-12
Phase II Study Results of Lisocabtagene Maraleucel in Large B-Cell Lymphoma: From a Nonuniversity Setting
Three Novel Regimens for Diffuse Large B-Cell Lymphoma: UNITY-NHL Study
FDA Brief: Priority Review for Lisocabtagene Maraleucel as Second-Line Therapy for LBCL
TP53 Alterations in Predicting Response to Immunotherapy for Large B-Cell Lymphoma
Using SHP1 Expression to Predict Response to Ibrutinib in Diffuse Large B-Cell Lymphoma
Parsaclisib in BTK Inhibitor–Naive Relapsed or Refractory Mantle Cell and Marginal Zone Lymphomas
Safety of Umbralisib in Treatment of Lymphomas Under Review by the FDA
FDA Approves Label Update to Axicabtagene Ciloleucel to Include Toxicity Management Strategy
Lisocabtagene Maraleucel Versus Chemotherapy in B-Cell Lymphoma: Interim Analysis of TRANSFORM Trial
FDA Brief: Bispecific CAR T-Cell Therapy Receives Fast Track Designation in DLBCL
Second-Line CAR T -Cell Therapy Versus Standard of Care in Large B-Cell Lymphoma: ZUMA-7 Trial
Phase IIb Trial of Umbralisib Plus Ublituximab in Marginal Zone Lymphoma
Long-Term Follow-Up of Maintenance Therapy Versus Retreatment With Rituximab for Follicular Lymphoma
CD19-Directed CAR T-Cell Therapy for Large B-Cell Lymphoma: 2-Year Follow-up Data
Polatuzumab Vedotin-piiq Combination Regimen in Newly Diagnosed DLBCL: POLARIX Trial
Chemotherapy-Free Regimen Under Study in Resistant Diffuse Large B-Cell Lymphoma
Preliminary Study Data on Glofitamab Plus Polatuzumab Vedotin-piiq in DLBCL
Naratuximab Emtansine Plus Rituximab in B-Cell Non-Hodgkin Lymphomas
CD19-Derived CAR Natural Killer Cell Therapy in Resistant B-Cell Lymphoma
Next-Generation BTK Inhibitor Under Study in Mantle Cell Lymphoma

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.